AbbVie to acquire Cerevel Therapeutics for $8.7bn
Emraclidine is a late-stage antipsychotic asset of Cerevel being analysed for the treatment of schizophrenia.
Ipsen and Genfit secure FDA priority review for chronic liver disease drug
Synplogen and Ginkgo Bioworks sign MoU for DNA manufacture
Dr Reddy’s and Coya sign licence for ALS combination therapy
Sosei wins South Korean approval for brain injury drug
Japan approves BMS’ Abecma for multiple myeloma treatment
Analysis
View More
Themes
View MoreHealth Canada authorises Novavax’s updated Covid-19 vaccine
The updated Covid-19 vaccine is also authorised for use in the US and the European Union.
More themes
Premium Insights
View MoreLeading innovators in nucleotide analogues for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover premium insights powered by our properietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
MSD reinforces Amazon partnership for faster AI-led drug discovery and development
Japan grants approval for CSL and Arcturus’ Covid-19 vaccine
Boehringer to leverage IBM’s technologies for antibody discovery
Japan approves Daiichi Sankyo’s Covid-19 booster vaccine